Mirati Therapeutics | MRTX - Betriebsaufwand



Betriebsaufwand Veränderung Datum
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amgen USD 11.69B 6.9B 2026-06
Astellas Pharma JPY 455.56B 33.8B 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Bayer EUR 9.88B 452M 2026-03
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Eisai JPY 209.6B 6.14B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Exelixis USD 359.47M 3.28M 2026-03
Gilead Sciences USD 3.95B 19.57B 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
J&J USD 17.83B 388M 2026-06
Merck USD 15.77B 2.4B 2026-06
Moderna USD 960M 817M 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Novartis USD 10.2B 912M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Puma Biotechnology USD 49.26M 3.2M 2024-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Takeda JPY 1.02T 89.68B 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06